Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A.

Matsumiya M, Stylianou E, Griffiths K, Lang Z, Meyer J, Harris SA, Rowland R, Minassian AM, Pathan AA, Fletcher H, McShane H.

PLoS One. 2013 Jul 3;8(7):e67922. doi: 10.1371/journal.pone.0067922. Print 2013.

2.

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.

Griffiths KL, Pathan AA, Minassian AM, Sander CR, Beveridge NE, Hill AV, Fletcher HA, McShane H.

PLoS One. 2011;6(8):e23463. doi: 10.1371/journal.pone.0023463. Epub 2011 Aug 26.

3.

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.

Pathan AA, Minassian AM, Sander CR, Rowland R, Porter DW, Poulton ID, Hill AV, Fletcher HA, McShane H.

Vaccine. 2012 Aug 17;30(38):5616-24. doi: 10.1016/j.vaccine.2012.06.084. Epub 2012 Jul 10.

4.

Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A.

Tanner R, Kakalacheva K, Miller E, Pathan AA, Chalk R, Sander CR, Scriba T, Tameris M, Hawkridge T, Mahomed H, Hussey G, Hanekom W, Checkley A, McShane H, Fletcher HA.

BMC Infect Dis. 2014 Dec 3;14:660. doi: 10.1186/s12879-014-0660-7.

5.

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.

Sander CR, Pathan AA, Beveridge NE, Poulton I, Minassian A, Alder N, Van Wijgerden J, Hill AV, Gleeson FV, Davies RJ, Pasvol G, McShane H.

Am J Respir Crit Care Med. 2009 Apr 15;179(8):724-33. doi: 10.1164/rccm.200809-1486OC. Epub 2009 Jan 16.

6.

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.

Tameris M, Geldenhuys H, Luabeya AK, Smit E, Hughes JE, Vermaak S, Hanekom WA, Hatherill M, Mahomed H, McShane H, Scriba TJ.

PLoS One. 2014 Feb 3;9(2):e87340. doi: 10.1371/journal.pone.0087340. eCollection 2014.

7.

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.

Satti I, Meyer J, Harris SA, Manjaly Thomas ZR, Griffiths K, Antrobus RD, Rowland R, Ramon RL, Smith M, Sheehan S, Bettinson H, McShane H.

Lancet Infect Dis. 2014 Oct;14(10):939-46. doi: 10.1016/S1473-3099(14)70845-X. Epub 2014 Aug 20.

8.

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.

McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, Fletcher HA, Hill AV.

Nat Med. 2004 Nov;10(11):1240-4. Epub 2004 Oct 24. Erratum in: Nat Med. 2004 Dec;10(12):1397.

PMID:
15502839
9.

Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A.

de Cassan SC, Pathan AA, Sander CR, Minassian A, Rowland R, Hill AV, McShane H, Fletcher HA.

Clin Vaccine Immunol. 2010 Jul;17(7):1066-73. doi: 10.1128/CVI.00047-10. Epub 2010 May 19. Erratum in: Clin Vaccine Immunol. 2011 Apr;18(4):696.

10.

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.

Brookes RH, Hill PC, Owiafe PK, Ibanga HB, Jeffries DJ, Donkor SA, Fletcher HA, Hammond AS, Lienhardt C, Adegbola RA, McShane H, Hill AV.

PLoS One. 2008 Aug 13;3(8):e2921. doi: 10.1371/journal.pone.0002921. Erratum in: PLoS One. 2011;6(2). doi:10.1371/annotation/5284a0b6-62a9-484e-80a4-a08c59b3b17c.

11.

Insulin infusion suppresses while glucose infusion induces Toll-like receptors and high-mobility group-B1 protein expression in mononuclear cells of type 1 diabetes patients.

Dandona P, Ghanim H, Green K, Sia CL, Abuaysheh S, Kuhadiya N, Batra M, Dhindsa S, Chaudhuri A.

Am J Physiol Endocrinol Metab. 2013 Apr 15;304(8):E810-8. doi: 10.1152/ajpendo.00566.2012. Epub 2013 Feb 12.

12.

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.

Pathan AA, Sander CR, Fletcher HA, Poulton I, Alder NC, Beveridge NE, Whelan KT, Hill AV, McShane H.

PLoS One. 2007 Oct 24;2(10):e1052. Erratum in: PLoS One. 2011;6(2).doi:10.1371/annotation/71208a01-eb32-469c-96ab-8d5e3c497fce.

13.

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response.

Matsumiya M, Harris SA, Satti I, Stockdale L, Tanner R, O'Shea MK, Tameris M, Mahomed H, Hatherill M, Scriba TJ, Hanekom WA, McShane H, Fletcher HA.

BMC Infect Dis. 2014 Jun 9;14:314. doi: 10.1186/1471-2334-14-314.

14.

Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin.

Vordermeier HM, Rhodes SG, Dean G, Goonetilleke N, Huygen K, Hill AV, Hewinson RG, Gilbert SC.

Immunology. 2004 Jul;112(3):461-70.

15.

Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.

Kolibab K, Yang A, Derrick SC, Waldmann TA, Perera LP, Morris SL.

Clin Vaccine Immunol. 2010 May;17(5):793-801. doi: 10.1128/CVI.00006-10. Epub 2010 Mar 31.

16.

Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.

White AD, Sibley L, Dennis MJ, Gooch K, Betts G, Edwards N, Reyes-Sandoval A, Carroll MW, Williams A, Marsh PD, McShane H, Sharpe SA.

Clin Vaccine Immunol. 2013 May;20(5):663-72. doi: 10.1128/CVI.00690-12. Epub 2013 Feb 27.

17.

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.

Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, Lang T, Veldsman A, Hatherill M, Merwe Lv, Fletcher HA, Mahomed H, Hill AV, Hanekom WA, Hussey GD, McShane H.

J Infect Dis. 2008 Aug 15;198(4):544-52. doi: 10.1086/590185. Erratum in: J Infect Dis. 2011 Jul;204(1):176.

18.

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.

Fletcher HA, Pathan AA, Berthoud TK, Dunachie SJ, Whelan KT, Alder NC, Sander CR, Hill AV, McShane H.

Vaccine. 2008 Sep 26;26(41):5269-75. doi: 10.1016/j.vaccine.2008.07.040. Epub 2008 Aug 3.

19.

[Novel vaccines against M. tuberculosis].

Okada M.

Kekkaku. 2006 Dec;81(12):745-51. Review. Japanese.

PMID:
17240920
20.

Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.

Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Mauff K, Hughes EJ, Moyo S, Brittain N, Lawrie A, Mulenga H, de Kock M, Gelderbloem S, Veldsman A, Hatherill M, Geldenhuys H, Hill AV, Hussey GD, Mahomed H, Hanekom WA, McShane H.

J Infect Dis. 2011 Jun 15;203(12):1832-43. doi: 10.1093/infdis/jir195.

Items per page

Supplemental Content

Write to the Help Desk